Research Topics
Genomes and Genes | A CarneroSummaryCountry: Spain Publications
| Collaborators
|
Detail Information
Publications
PTEN, more than the AKT pathwayCarmen Blanco Aparicio
Experimental Therapeutics Programme, Spanish National Cancer Centre CNIO, C Melchor Fernandez Almagro 3, 28029 Madrid, Spain
Carcinogenesis 28:1379-86. 2007..However, AKT is more than a passive bridge toward PTEN tumorigenesis, since its expression not only allows but also enforces and accelerates the tumorigenic process in combination with other oncogenes...
The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implicationsAmancio Carnero
Experimental Therapeutics Programme, Spanish National Cancer Centre CNIO, C Melchor Fernandez Almagro 3, 28029 Madrid, Spain
Curr Cancer Drug Targets 8:187-98. 2008..Additionally, the binding of PI3K to oncogenic ras is essential for the transforming properties of ras. In summary, the data strongly support the view of the PTEN/PI3K/AKT pathway as an important target for drug discovery...
The PKB/AKT pathway in cancerAmancio Carnero
Experimental Therapeutics Programme, Spanish National Cancer Centre CNIO, C Melchor Fernandez Almagro 3, 28029 Madrid, Spain
Curr Pharm Des 16:34-44. 2010..These proteins are kinases, which are very "druggable" targets a priori, and, according to the "addiction hypothesis", cancer cells with the activated pathway will be more dependent on its activity for their survival...
Using multiplexed regulation of luciferase activity and GFP translocation to screen for FOXO modulatorsFabian Zanella
Experimental Therapeutics Programme, Centro Nacional de Investigaciones Oncologicas, Melchor Fernandez Almagro 3, 28029 Madrid, Spain
BMC Cell Biol 10:14. 2009..We developed U2transLUC, an assay system in which luciferase and fluorescent read-outs can be multiplexed to provide a powerful cell-based high content screening method...
Absence of p21WAF1 cooperates with c-myc in bypassing Ras-induced senescence and enhances oncogenic cooperationAmancio Carnero
Experimental Therapeutics Programme, Centro Nacional de Investigaciones Oncologicas CNIO, Madrid, Spain
Oncogene 23:6006-11. 2004..Thus, the reciprocal cooperation between myc and ras in a p21-null background during cellular immortalization lead to increased oncogenic cooperation between ras and myc...
High throughput screening in drug discoveryA Carnero
Experimental Therapeutics Programme, CNIO, Madrid, Spain
Clin Transl Oncol 8:482-90. 2006..To that end, new developments in large-scale cell biology and compound library design in silico have evolved to obtain data with higher predictability of clinical efficacy...
Novel inhibitors of the PI3K familyAmancio Carnero
Centro Nacional de Investigaciones Oncologicas, Experimental Therapeutics Program, Melchor Fernandez Almagro, 3, Madrid, 28029, Spain
Expert Opin Investig Drugs 18:1265-77. 2009..Indeed, many companies and academic laboratories have initiated a variety of approaches to inhibit the PI3K pathway at different points. In this work, we review the targeting of PI3K protein for therapeutical intervention...
Cellular senescence bypass screen identifies new putative tumor suppressor genesJ F M Leal
Experimental Therapeutics Programme, Centro Nacional de Investigaciones Oncologicas CNIO, Madrid, Spain
Oncogene 27:1961-70. 2008..Our data suggest that the three genes identified in the genome-wide loss-of-function genetic screen are putative tumor suppressors located at 15q21.2; 7q35 and 14q32.33...
Trans-platinum(II) complexes with cyclohexylamine as expectator ligand induce necrosis in tumour cells by inhibiting DNA synthesis and RNA transcriptionV Cepero
CNIO, Experimental Therapeutics Program, Madrid, Spain
Clin Transl Oncol 9:521-30. 2007..One line of work is focussed on trans platinum complexes, some of which exhibit antitumour activity similar to or even higher than that of their cis counterparts...
Identification of transcripts specific for physiological gene activation by platelet-derived growth factor (PDGF)-B in intact brain tissueOliver Renner
Experimental Therapeutics Programme, Spanish National Cancer Centre, E 28029 Madrid, Spain
J Cell Biochem 95:859-67. 2005....
Non-neutral role of replicative senescence in tissue homeostasis and tumorigenesisJuan F Poyatos
Evolutionary Systems Biology Initiative, Structural and Computational Biology Program, Spanish National Cancer Center CNIO, Melchor Fernandez Almagro 3, Madrid 28029
J Theor Biol 230:333-41. 2004..The models introduced, though simple, help to integrate experimental information relating tumorigenesis with cellular and organism aging phenomena...
Targeting the cell cycle for cancer therapyA Carnero
Experimental Therapeutics Programme, Centro Nacional de Investigaciones Oncologicas CNIO, c Melchor Fernandez Almagro no 3, 28029 Madrid, Spain
Br J Cancer 87:129-33. 2002..Thus, although too early to provide a cell cycle target based new commercial drug, there is no doubt that it will be an excellent source of new anticancer compounds...
Inhibition of phosphatidylinositol-3-kinase synergizes with gemcitabine in low-passage tumor cell lines correlating with Bax translocation to the mitochondriaCarmen Blanco-Aparicio
Experimental Therapeutics Programme, Spanish National Cancer Center (CNIO, Madrid, Spain
Anticancer Drugs 16:977-87. 2005..These results facilitate the exploration of potential synergism between chemotherapeutic treatment and the search for others that can account for similar molecular mechanisms of cooperation...
Chemical interrogation of FOXO3a nuclear translocation identifies potent and selective inhibitors of phosphoinositide 3-kinasesWolfgang Link
From the Experimental Therapeutics Programme, Spanish National Cancer Research Center CNIO, Melchor Fernandez Almagro 3, 28029 Madrid, Spain
J Biol Chem 284:28392-400. 2009..This leads to the synthesis of ETP-45658, which is a potent and selective inhibitor of phosphoinositide 3-kinases and demonstrates mechanism of action in tumor cell lines and in vivo in treated mice...
Human TRIB2 is a repressor of FOXO that contributes to the malignant phenotype of melanoma cellsF Zanella
Experimental Therapeutics Program, Centro Nacional de Investigaciones Oncologicas CNIO, Madrid 28029, Spain
Oncogene 29:2973-82. 2010..Altogether, our results show the potential of large-scale cell-based RNAi screens to identify promising diagnostic markers and therapeutic targets...
Targeted search for anticancer drugs--CNIO cancer conference. 16-18 March, Madrid, SpainJuan Carlos Lacal
Instituto de Investigaciones Biomedicas, Consejo Superior de Investigaciones Cientificas, Madrid, Spain
IDrugs 6:437-41. 2003....
Characterization of the p53 response to oncogene-induced senescenceLidia Ruiz
Experimental Therapeutics Programme, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain
PLoS ONE 3:e3230. 2008..It is a live debate whether these outcomes are influenced by quantitative or qualitative mechanisms. Furthermore, the relative contribution of p53 to Ras-induced senescence is also matter of controversy...
MAP17 inhibits Myc-induced apoptosis through PI3K/AKT pathway activationMaria V Guijarro
Experimental Therapeutics Programme, Centro Nacional de Investigaciones Oncologicas, Madrid 28029, Spain
Carcinogenesis 28:2443-50. 2007..Our data indicate that MAP17 protein activates AKT through ROS and this is determinant to confer resistance to Myc-induced apoptosis in the absence of serum...
Genetic modelling of the PTEN/AKT pathway in cancer researchOliver Renner
Experimental Therapeutics Programme, Spanish National Cancer Centre CNIO, Madrid, Spain
Clin Transl Oncol 10:618-27. 2008..This review will summarise some of the key animal models which have helped us to understand this signalling network and its contribution to tumorigenesis...
Mst1, RanBP2 and eIF4G are new markers for in vivo PI3K activation in murine and human prostateOliver Renner
Experimental Therapeutics Programme, Spanish National Cancer Centre CNIO, C Melchor Fernandez Almagro3, Madrid, Spain
Carcinogenesis 28:1418-25. 2007..Since they define overlapping but not identical subsets of the tested tissue panel, a combination of all four markers might lead to a more accurate diagnosis of the status of the PI3K-signaling cascade in cancer patients...
Overexpression of PKC zeta in NIH3T3 cells does not induce cell transformation nor tumorigenicity and does not alter NF kappa B activityS Montaner
, CSIS, Madrid, Spain
Oncogene 10:2213-20. 1995..Thus, mammalian PKC zeta is most likely not directly involved in the regulation of cell proliferation in fibroblasts nor affects directly or indirectly the activation of NF kappa B...
Genetic cooperation between p21Cip1 and INK4 inhibitors in cellular senescence and tumor suppressionV Quereda
Cell Division and Cancer Group, Centro Nacional de Investigaciones Oncologicas CNIO, Madrid, Spain
Oncogene 26:7665-74. 2007....
Large scale genetic screen identifies MAP17 as protein bypassing TNF-induced growth arrestM V Guijarro
Experimental Therapeutics Program, Centro Nacional de Investigaciones Oncologicas CNIO, Madrid, Spain
J Cell Biochem 101:112-21. 2007..However, MAP17 mRNA expression did not correlate with TNF resistance. Our data indicates that although MAP17 expression might bypass TNF-induced growth arrest, it is not the only determinant of this response...
Chemical genetic analysis of FOXO nuclear-cytoplasmic shuttling by using image-based cell screeningFabian Zanella
Experimental Therapeutics Program, Centro Nacional de Investigaciones Oncologicas CNIO, Melchor Fernandez Almagro 3, 28029 Madrid, Spain
Chembiochem 9:2229-37. 2008..Our data illustrate the potential of chemical genetics when combined with robust and sensitive high-content-screening technology...
Membrane localization of all class I PI 3-kinase isoforms suppresses c-Myc-induced apoptosis in Rat1 fibroblasts via AktWolfgang Link
Experimental Therapeutics Program, Centro Nacional de Investigaciones Oncologicas, Melchor Fernandez Almagro, 3, 28029 Madrid, Spain
J Cell Biochem 95:979-89. 2005..p110 isoform-mediated protection from cell death was abrogated upon expression of a kinase-negative version of Akt...
Activation of phosphatidylinositol 3-kinase by membrane localization of p110alpha predisposes mammary glands to neoplastic transformationOliver Renner
Experimental Therapeutics Program and Biotechnology Program, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain
Cancer Res 68:9643-53. 2008....
Using cells devoid of RAS proteins as tools for drug discoveryJelena Urosevic
Molecular Oncology Programme, Centro Nacional de Investigaciones Oncologicas CNIO, Madrid, Spain
Mol Carcinog 48:1038-47. 2009..The use of cell lines whose proliferative properties exclusively depend on selective targets provide a novel strategy to analyze the specificity of selective inhibitors designed against molecular targets implicated in human cancer...
Mouse models to decipher the PI3K signaling network in human cancerOliver Renner
Experimental Therapeutics Program, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain
Curr Mol Med 9:612-25. 2009..Using these models for drug testing may enable more accurate prediction of the effects that a specific drug will have on a patient...
Cellular senescence induced by p53-ras cooperation is independent of p21waf1 in murine embryo fibroblastsMaria E Castro
Experimental Therapeutics Program, Centro Nacional de Investigaciones Oncologicas CNIO, Melchor Fernandez Almagro, 3, 28029, Madrid Spain
J Cell Biochem 92:514-24. 2004..Our results indicate that oncogenic activation of the Ras pathway in murine fibroblasts converts p53 into a senescence inducer through a p21waf1-independent mechanism...
Adding more content to screening: reactivation of FOXO as a therapeutic strategyFabian Zanella
Experimental Therapeutics Programme, Spanish National Cancer Research Centre, Madrid, Spain
Clin Transl Oncol 11:651-8. 2009..Here, we review the development of HCS platforms to identify molecules influencing FOXO nuclear relocation and activation as pharmacological targets, their applicability and the future directions of the screening field...
Exploring the gain of function contribution of AKT to mammary tumorigenesis in mouse modelsCarmen Blanco-Aparicio
Experimental Therapeutics Programme, Spanish National Cancer Research Centre, Madrid, Spain
PLoS ONE 5:e9305. 2010....
Overexpression of cyclin D1 inhibits TNF-induced growth arrestVictoria Moneo
Experimental Therapeutics Program, Centro Nacional de Investigaciones Oncologicas CNIO, Melchor Fernandez Almagro, 3, 28029, Madrid, Spain
J Cell Biochem 89:484-99. 2003..Our results confirm that p21(waf1) has an essential role in TNF-induced arrest and that the deregulation of cyclin D1 may be one of the mechanisms to escape physiological signals to restrict tumoral growth...
Loss-of-function genetic screening identifies a cluster of ribosomal proteins regulating p53 functionMaria E Castro
Experimental Therapeutics Programme, Centro Nacional de Investigaciones Oncologicas, C Melchor Fernández Almagro, 3, 28029 Madrid, Spain
Carcinogenesis 29:1343-50. 2008..Interestingly, in most cases, the reduction of ribosomal protein mRNAs occurs only to 50%. Our data suggest that ribosomal protein imbalance might contribute to p53 regulation through the ribosomal biogenesis checkpoint...
An HTS approach to screen for antagonists of the nuclear export machinery using high content cell-based assaysFabian Zanella
Experimental Therapeutics Program, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain
Assay Drug Dev Technol 5:333-41. 2007..76. In summary, U2nesRELOC is a cell-based nuclear export assay suitable for high throughput screening, providing counterscreens for pathway deconvolution...
Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomasCristina Rodriguez-Antona
Hereditary Endocrine Cancer Group, Spanish National Cancer Centre, c Melchor Fernandez Almagro no 3, 28029 Madrid, Spain
Blood 110:3345-51. 2007..In conclusion, a high CYP3A4 tumoral expression could be useful to predict poor response to the standard PTCL chemotherapy; in these cases alternative chemotherapy combinations or doses should be explored...
PPP1CA contributes to the senescence program induced by oncogenic RasMaria E Castro
Experimental Therapeutics Programme, Spanish National Cancer Research Center CNIO, 28029 Madrid, Spain
Carcinogenesis 29:491-9. 2008..We propose that oncogenic stress induced by ras causes ceramide accumulation, therefore, increasing PPP1CA activity, pRb dephosphorylation and onset of the p53-induced arrest, contributing to tumor suppression...
Understanding FOXO, new views on old transcription factorsFabian Zanella
Experimental Therapeutics Programme, Spanish National Cancer Research Centre, Madrid, Spain
Curr Cancer Drug Targets 10:135-46. 2010..Therefore, understanding the modulation of FOXO transcription factors will allow the design of new compounds with antitumor potential...
MAP17 enhances the malignant behavior of tumor cells through ROS increaseMaria V Guijarro
Experimental Therapeutics Program, Centro Nacional de Investigaciones Oncologicas, Melchor Fernandez Almagro, 3, 28029 Madrid, Spain
Carcinogenesis 28:2096-104. 2007..Our work shows the tumorigenic capability of MAP17 through a connection between Na+-coupled co-transporters and ROS...
Cooperation between Cdk4 and p27kip1 in tumor development: a preclinical model to evaluate cell cycle inhibitors with therapeutic activityRocio Sotillo
Molecular Oncology, Centro Nacional de Investigaciones Oncologicas CNIO, Madrid, Spain
Cancer Res 65:3846-52. 2005..These data suggest that genetically engineered tumor models involving key cell cycle regulators are a valuable tool to evaluate drugs with potential therapeutic benefit in human cancer...
A dual-color fluorescence-based platform to identify selective inhibitors of Akt signalingAranzazu Rosado
Experimental Therapeutics Program, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain
PLoS ONE 3:e1823. 2008..However, rational target-orientated approaches to cell based drug screens for anti-cancer agents have historically been compromised by the notorious absence of suitable control cells...
Mitotic catastrophe cell death induced by heat shock protein 90 inhibitor in BRCA1-deficient breast cancer cell linesMagdalena Zajac
Grupo Genética Humana, Centro Nacional de Investigaciones Oncologicas, Melchor Fernandez Almagro 3, Madrid, Spain
Mol Cancer Ther 7:2358-66. 2008..Our observations show that BRCA1 mediates G(2)-M transition mainly through chek1 on 17-allyloamino-17-demethoxy-geldanamycin treatment...
Structure-activity relationship of new trans-platinum(II) and (IV) complexes with cyclohexylamine. Interference with cell cycle progression and induction of cell deathAna M González Vadillo
Departamento de Quimica Inorganica, Facultad de Ciencias, Universidad Autonoma de Madrid, Cantoblanco, 28049 Madrid, Spain
J Inorg Biochem 101:551-8. 2007..Mechanistically, the antitumor activity correlates with a blockade of the cell cycle in S phase and a complete abolishment of G2/M checkpoint arrest suggesting physical interaction of compound with DNA inhibiting S phase transition...
Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patientsNerea Martinez
Molecular Pathology Programme, Centro Nacional de Investigaciones Oncologicas, C Melchor Fernandez Almagro 3, E 28029 Madrid, Spain
Mol Cancer Ther 4:814-23. 2005..The transcriptional signature described here may lead to the identification of ET-743 downstream mediators and transcription regulators and the proposal of strategies by which ET-743-sensitive tumors may be identified...
Cell cycle deregulation: a common motif in cancerMarcos Malumbres
Molecular Oncology Program, , Madrid
Prog Cell Cycle Res 5:5-18. 2003..Manipulation of these control mechanisms provides new avenues for the design of advanced therapeutic strategies against tumor development...
Glycolytic enzymes can modulate cellular life spanHiroshi Kondoh
Wolfson Institute for Biomedical Research, University College London, London Research Institute, London, United Kingdom
Cancer Res 65:177-85. 2005..Because wild-type p53 down-regulates PGM, mutation of p53 can facilitate immortalization via effects on PGM levels and glycolysis...
Roscovitine targets, protein kinases and pyridoxal kinaseStephane Bach
CNRS, Cell Cycle Group, UPS 2682 and UMR 2775, Station Biologique, BP 74, 29682 Roscoff Cedex, Bretagne, France
J Biol Chem 280:31208-19. 2005..These results could help in interpreting the cellular actions of (R)-roscovitine but also in guiding the synthesis of more selective roscovitine analogs...
Immortalization of primary human prostate epithelial cells by c-MycJesus Gil
Molecular Oncology Laboratory, Cancer Research UK, London Research Institute, United Kingdom
Cancer Res 65:2179-85. 2005..These results give a partial explanation for the physiologic role of c-Myc overexpression in prostate cancer...
CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locusDavid Bernard
Laboratory of Molecular Virology, Faculty of Medicine, Free University of Brussels, Brussels, Belgium
Oncogene 24:5543-51. 2005..Together, these data suggest that CBX7 represses p16Ink4a and p14Arf expression in normal and tumor-derived prostate cells, affecting their growth depending on the status of the p16Ink4a/Rb and the p14Arf/p53 pathways...
New trans-platinum drugs with phosphines and amines as carrier ligands induce apoptosis in tumor cells resistant to cisplatinFrancisco J Ramos Lima
Departamento de Quimica Inorganica, Universidad Autonoma de Madrid, 28049 Madrid, Spain
J Med Chem 50:2194-9. 2007..Our data indicate that our compounds are not cross-resistant with cisplatin and might be promising agents in the treatment of tumors unresponsive to cisplatin...
